These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29941212)

  • 1. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
    Jeong A; Wong M
    Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
    Aronica E; Specchio N; Luinenburg MJ; Curatolo P
    Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
    Wong M
    Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 13. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
    Jeong A; Wong M
    Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
    Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
    Wong M
    Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
    Palavra F; Robalo C; Reis F
    Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P; Moavero R; van Scheppingen J; Aronica E
    Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis.
    Zhang MN; Zou LP; Wang YY; Pang LY; Ma SF; Huang LL; Gao Y; Lu Q; Franz DN
    Seizure; 2018 Aug; 60():86-90. PubMed ID: 29929111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.
    He W; Chen J; Wang YY; Zhang MN; Qian-Lu ; Wang QH; Luo XM; Chen XQ; Zou LP
    Seizure; 2020 Jul; 79():20-26. PubMed ID: 32416565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.